v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | NCT04345601 |
Full text link
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
|
First author
Last imported at : March 8, 2023, 4 a.m. Source : ClinicalTrials.gov |
|
Contact
Last imported at : March 8, 2023, 4 a.m. Source : ClinicalTrials.gov |
Not reported |
Registration date
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2020-04-14 |
Recruitment status
Last imported at : March 8, 2023, 4 a.m. Source : ClinicalTrials.gov |
Completed |
Study design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
RCT |
Allocation
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Randomized |
Design
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Parallel |
Masking
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Open label |
Center
Last imported at : March 15, 2023, 4 a.m. Source : ClinicalTrials.gov |
single-center |
Study aim
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment |
Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
inclusion criteria: 18 years or older confirmed sars-cov2 infection real-time reverse transcription polymerase chain reaction (rt-pcr) assay moderate or severe ards, based on the degree of impairment of oxygenation as defined by the ratio of arterial oxygen tension to fraction of inspired oxygen (pao2/fio2): moderate ards: pao2/fio2 100-200 mmhg or severe ards: pao2/fio2 ≤100 mmhg if on invasive or noninvasive (bipap) mechanical ventilator, peep ≥5 cm h2o bilateral opacities present on chest radiograph or computed tomographic (ct) scan, that are not fully explained by pleural effusions, lung collapse, or lung nodules. |
Exclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
currently receiving extracorporeal membrane oxygenation (ecmo) severe chronic respiratory disease requiring use of home oxygen pregnant or lactating known hypersensitivity to dimethyl sulfoxide (dmso) unstable hemodynamics (ventricular tachycardia or fibrillation) uncontrolled bacterial or fungal co-infection any end-stage organ disease or condition, which in the opinion of the investigator, makes the patient an unsuitable candidate for treatment inability to obtain informed consent (from patient or legally appropriate proxy) presence of any contraindication to receiving prophylactic low dose unfractionated or low molecular weight heparin. |
Number of arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
2 |
Funding
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Baylor College of Medicine |
Inclusion age min
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
18 |
Inclusion age max
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
100 |
Countries
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
United States |
Type of patients
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Moderate/severe disease at enrollment |
Severity scale
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
4: Moderate/severe disease at enrollment |
Total sample size
Last imported at : March 8, 2023, 4 a.m. Source : ClinicalTrials.gov |
28 |
primary outcome
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
Treatment-related serious adverse events (tSAEs);Change in clinical status at day 14 |
Notes
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
None |
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m. Source : ClinicalTrials.gov |
Phase 1/Phase 2 |
Arms
Last imported at : Oct. 26, 2020, 11:31 p.m. Source : ClinicalTrials.gov |
[{"arm_notes": "", "treatment_id": 793, "treatment_name": "Mesenchymal stromal cells", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |